United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

23 Jun 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Cohen, Ron 

Dr. Ron Cohen, M.D., is President, Chief Executive Officer and Director of Acorda Therapeutics, Inc. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. He received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of Dyax Corp. Dr. Cohen previously was a Director and Chairman of the New York Biotechnology Association. He currently serves as a member of the Executive Committee and as the Chairman of the Emerging Company Section of the board of the Biotechnology Industry Organization (BIO). He also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment’s CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and an inductee into the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA "The Cure Starts Here" Business Leader of the Year. Dr. Cohen is the principal strategist in the Company’s commitment to being a fully-integrated biopharmaceutical company that is a leading innovator in neurology.

Basic Compensation

Total Annual Compensation, USD 1,397,430
Restricted Stock Awards, USD 700,413
Long-Term Incentive Plans, USD --
All Other, USD 1,947,340
Fiscal Year Total, USD 4,045,180

Options Compensation

  Quantity Market Value
Exercisable 665,721 6,186,790.00
Unexercisable 38,452 148,425.00
Exercised 51,265 1,404,180.00
Name Fiscal Year Total

Ron Cohen


David Lawrence


Andrew Blight


Jane Wasman


Burkhard Blank


Andrew Hindman

As Of  30 Dec 2014